Rapt Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy RAPT

*Your capital is at risk

$58.02

+0 (+0%)

At Close: Jun 01, 2026

RAPT Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.46. In total, the insiders bought 7.63M and sold 1.29M RAPT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.46
● Buy	7.63M shares
● Sell	1.29M shares
38% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Mar 03, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -42.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	4 561 Value: $168.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	1 618 Value: $270.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	938 Value: $212.1K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	417 Value: $40.0K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	521 Value: $56.8K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Kozick Linda Director	Director	521 Value: $25.8K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	32 229 Value: $239.8K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	4 561 Value: $168.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	1 618 Value: $270.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	560 Value: $82.2K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	1 063 Value: $116.0K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	484 Value: $85.1K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	938 Value: $144.8K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	478 Value: $84.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	938 Value: $212.1K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	498 Value: $84.7K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	2 813 Value: $619.5K
Mar 03, 2026 Sell	Common Stock U-Tender	Gray Mary Ann Director	Director	4 956 Value: $0
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Lyons-williams Lori Director	Director	32 229 Value: $239.8K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Lyons-williams Lori Director	Director	4 561 Value: $168.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Lyons-williams Lori Director	Director	1 618 Value: $270.9K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Lyons-williams Lori Director	Director	1 063 Value: $116.0K
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Lyons-williams Lori Director	Director	2 813 Value: $861.5K
Mar 03, 2026 Sell	Common Stock U-Tender	Lyons-williams Lori Director	Director	4 956 Value: $0
Mar 03, 2026 Sell	Director Stock Option (right to buy) D-Return	Gray Mary Ann Director	Director	7 650 Value: $74.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RAPT THERAPEUTICS, INC.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...

Read Full Profile Here